Abbott Laboratories (ABT) Net Cash Flow (2009 - 2026)

Abbott Laboratories has disclosed Net Cash Flow across 18 years of filings, most recently posting -$1.7 billion for Q2 2026.

• In Q2 2026, Net Cash Flow fell 562.77% year-over-year to -$1.7 billion; the TTM figure through Jun 2026 stood at -$1.8 billion (down 2750.0% YoY), while the FY2025 annual figure was $835.0 million, up 2.33% from the prior year.
• Net Cash Flow came in at -$1.7 billion for Q2 2026 at Abbott Laboratories, roughly flat from -$1.7 billion in the prior quarter.
• In the past five years, Net Cash Flow ranged from a high of $1.3 billion in Q2 2022 to a low of -$2.1 billion in Q1 2022.
• Average Net Cash Flow over 5 years is -$250.3 million, with a median of $151.5 million recorded in 2023.
• Year-over-year, Net Cash Flow surged 612.77% in 2025 and sank 562.77% in 2026.
• Over 5 years, Net Cash Flow stood at $237.0 million in 2022, then plunged by 31.65% to $162.0 million in 2023, then fell by 12.96% to $141.0 million in 2024, then surged by 612.77% to $1.0 billion in 2025, then sank by 269.45% to -$1.7 billion in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were -$1.7 billion in Q2 2026, -$1.7 billion in Q1 2026, and $1.0 billion in Q4 2025.